The Development of Novel Antimicrobial Materials to Prevent Pathogenic Infections

预防病原感染的新型抗菌材料的开发

• 批准号: 10031976
• 金额: $ 35.09万
• 依托单位: METALLOBIO LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10031976
• 关键词: Development; Novel; Antimicrobial; Materials; Prevent

Antimicrobial resistance, AMR, is globally responsible for 1.2 million annual fatalities. Antimicrobial resistance, AMR, is already responsible for 1.2 million annual fatalities. Failure to address the issue by 2050 could result in 10 million deaths per year, costing the global economy £66 trillion. To put this into context, the predicted death rates for cancer will be 8.2 million by the same year. As current treatment and preventative antimicrobial technologies fail, minor injuries and simple surgeries, such as a scratch on the knee, could soon become fatal. To address this global healthcare emergency the World Health Organisation, WHO, have highlighted there is a clinical unmet need for novel technologies that can treat and prevent such pathogenic diseases. At MetalloBio we are directly answering this unmet need, in line with the UK Government's 20-year vision to control and contain AMR by 2040\. As part of highly skilled team, MetalloBio have developed two lead antimicrobial additives, that can be incorporated into different materials and coatings. These materials can be applied to medical and non-medical applications such as catheter coatings, orthopedics, wound care, paints, textiles and food packaging. MetalloBio's antimicrobial functionalised materials will be able to prevent infection, transmission and spread of harmful pathogens, improving human health and patient quality of life.The antimicrobial additives have higher activities than clinical antibiotics and current antimicrobial additives, but crucially this activity is retained against drug-resistant bacteria, including those highlighted by the WHO as a critical priority. The complexes have a modular synthesis, like Lego, we can exchange the "building blocks" of our additives to make a whole series of these complexes. Additionally, they are non-toxic and highly active when incorporated into different polymeric materials. As these complexes are highly innovative, and radically different from anything on the market, the likelihood of emergence of resistance is highly reduced.This project will directly build upon preclinical data on the additives, and proof-of-concept coating studies, to optimise our antimicrobial materials. Antimicrobial and antibiofilm efficacy studies will be completed on a broad-spectrum of pathogens and the coatings will be applied to a number of different materials to broaden the application potential. The recent COVID-19 pandemic highlighted the catastrophic effects of a global pandemic, increasing MetalloBio's technology's application potential will help in the fight to prevent AMR causing the next pandemic. MetalloBio will work closely with commercial partners to ensure the technology will be applicable in commercial environments.

抗生素耐药性 (AMR) 在全球范围内每年造成 120 万人死亡。抗菌素耐药性（AMR）已导致每年 120 万人死亡。如果到 2050 年未能解决这一问题，每年可能会导致 1000 万人死亡，给全球经济造成 66 万亿英镑的损失。考虑到这一点，预计同年癌症死亡率将达到 820 万人。由于目前的治疗和预防性抗菌技术失败，轻伤和简单的手术（例如膝盖划伤）可能很快就会致命。为了应对这一全球医疗紧急情况，世界卫生组织强调，临床上对治疗和预防此类致病性疾病的新技术的需求尚未得到满足。在 MetalloBio，我们正在直接满足这一未满足的需求，符合英国政府到 2040 年控制和遏制抗菌素耐药性的 20 年愿景。作为高技能团队的一部分，MetalloBio 开发了两种领先的抗菌添加剂，可以融入不同的材料和涂层中。这些材料可应用于医疗和非医疗应用，例如导管涂层、整形外科、伤口护理、油漆、纺织品和食品包装。 MetalloBio的抗菌功能化材料将能够预防有害病原体的感染、传播和扩散，改善人类健康和患者的生活质量。抗菌添加剂的活性比临床抗生素和现有的抗菌添加剂更高，但最重要的是，这种活性保留了针对耐药细菌的能力，包括那些被世界卫生组织强调为关键优先事项的细菌。这些复合体具有模块化合成，就像乐高一样，我们可以交换添加剂的“积木”来制作一系列这些复合体。此外，当掺入不同的聚合物材料中时，它们是无毒且高活性的。由于这些复合物具有高度创新性，并且与市场上的任何产品完全不同，因此出现耐药性的可能性大大降低。该项目将直接基于添加剂的临床前数据和概念验证涂层研究，以优化我们的抗菌材料。抗菌和抗生物膜功效研究将针对广谱病原体完成，涂层将应用于许多不同的材料以拓宽应用潜力。最近的 COVID-19 大流行凸显了全球大流行的灾难性影响，增加 MetalloBio 技术的应用潜力将有助于防止 AMR 引起下一次大流行。 MetalloBio将与商业合作伙伴密切合作，确保该技术适用于商业环境。